Lytix Biopharma AS - ESG Rating & Company Profile powered by AI
Check the end of this webpage for potential risks for Lytix Biopharma AS based on industry, location and size. This assessment of Lytix Biopharma AS employs information from across the web and also from available documents by Lytix Biopharma AS. The analysis of Lytix Biopharma AS is prepared by All Street Sevva using leading machine learning.
Lytix Biopharma AS in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.2; made up of an environmental score of 5.3, social score of 3.2 and governance score of 4.0.
4.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 951 | Purple Biotech Ltd | 4.3 | High |
| 951 | Vectura Group Services Ltd | 4.3 | High |
| 969 | Lytix Biopharma AS | 4.2 | High |
| 969 | Botanix Pharmaceuticals Ltd | 4.2 | High |
| 969 | Arvinas Inc | 4.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Lytix Biopharma AS have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Lytix Biopharma AS disclose current and historical energy intensity?
Sign up for free to unlockDoes Lytix Biopharma AS report the average age of the workforce?
Sign up for free to unlockDoes Lytix Biopharma AS reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Lytix Biopharma AS disclose its ethnicity pay gap?
Sign up for free to unlockDoes Lytix Biopharma AS disclose cybersecurity risks?
Sign up for free to unlockDoes Lytix Biopharma AS offer flexible work?
Sign up for free to unlockDoes Lytix Biopharma AS have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Lytix Biopharma AS disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Lytix Biopharma AS conduct supply chain audits?
Sign up for free to unlockDoes Lytix Biopharma AS disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Lytix Biopharma AS conduct 360 degree staff reviews?
Sign up for free to unlockDoes Lytix Biopharma AS disclose the individual responsible for D&I?
Sign up for free to unlockDoes Lytix Biopharma AS disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Lytix Biopharma AS disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Lytix Biopharma AS disclose water use targets?
Sign up for free to unlockDoes Lytix Biopharma AS have careers partnerships with academic institutions?
Sign up for free to unlockDid Lytix Biopharma AS have a product recall in the last two years?
Sign up for free to unlockDoes Lytix Biopharma AS disclose incidents of discrimination?
Sign up for free to unlockDoes Lytix Biopharma AS allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Lytix Biopharma AS issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Lytix Biopharma AS disclose parental leave metrics?
Sign up for free to unlockDoes Lytix Biopharma AS disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Lytix Biopharma AS disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Lytix Biopharma AS disclose the pay ratio of women to men?
Sign up for free to unlockDoes Lytix Biopharma AS support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Lytix Biopharma AS disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Lytix Biopharma AS reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Lytix Biopharma AS involved in embryonic stem cell research?
Sign up for free to unlockDoes Lytix Biopharma AS disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Lytix Biopharma AS disclose its waste policy?
Sign up for free to unlockDoes Lytix Biopharma AS report according to TCFD requirements?
Sign up for free to unlockDoes Lytix Biopharma AS disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Lytix Biopharma AS disclose energy use targets?
Sign up for free to unlockDoes Lytix Biopharma AS disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Lytix Biopharma AS have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Lytix Biopharma AS
These potential risks are based on the size, segment and geographies of the company.
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. It has a strategic partnership with Aurelius Biotherapeutics LLC to investigate and develop LTX-122 for the veterinary medicine market. The company was founded in 2003 and is based in Oslo, Norway.